Feeding the Need: Domino’s® is Giving Away 10 Million Slices of Pizza Nationwide

April 6, 2020

Every Domino’s store will donate 200 pizzas within their local communities

ANN ARBOR, Michigan, April 6, 2020 /PRNewswire-HISPANIC PR WIRE/ — Domino’s Pizza, Inc. (NYSE: DPZ) and its nationwide system of franchisees are banding together during this unprecedented crisis to do something we already do well every day – feeding people pizza. Domino’s company-owned and franchised stores throughout the U.S. will donate roughly 10 million slices of pizza within their local communities, starting this week.

Domino’s is partnering with its franchisees as part of this national effort, so that hospitals and medical centers, schoolkids and their families, health departments, grocery store workers, and others in need can enjoy a hot, delicious pizza. Domino’s franchisees, corporate managers and their local store employees know their neighborhoods best and will begin feeding the need they see around them this week by providing pizza to the people and organizations that are meaningful to their communities. All 6,126 stores nationwide are expected to be a part of this effort.

“We have a long history of feeding people during times of crisis and uncertainty. When we were looking at how we could help, we knew we could use the reach of our national brand to make a difference in thousands of local neighborhoods,” said Russell Weiner, Domino’s chief operating officer and president of the Americas. “We have franchisees and company-owned stores all over the country already doing amazing work in their communities and we know that by amplifying those efforts together we will be able to help even more people who are struggling right now.”

Domino’s franchisees are already out helping their local communities.

“We empowered our managers to look for opportunities in their local neighborhoods to donate pizzas to those in need,” said Domino’s franchisee Pat Farmer, who owns stores in the Seattle–Tacoma area. “It could be for families, frontline workers or even those showing up to work at our grocery stores. Stores are now actively looking for who they can help next. They have pride in how they’re making a difference during difficult times.”

“We take our responsibility seriously and we are honored that we can provide meals to those in need, as well as those who are working to save lives during this difficult time,” said Memphis-area Domino’s franchisee Jason Shifflett.

Shifflett has committed to donating an additional 1,000 pizzas to those in need in his community. San Diego franchisee Shane Casey is matching the 1,000-pizza commitment in his Southern California neighborhoods. Franchisee Jim Gronemann has already personally handed out pizzas to families in LaPorte, Indiana and has pledged to do so weekly. Domino’s will continue to share stories of franchisees and corporate store teams who are making a difference in their communities at biz.dominos.com/web/media/stories.

About Domino’s Pizza^®Founded in 1960, Domino’s Pizza is the largest pizza company in the world based on retail sales, with a significant business in both delivery and carryout pizza. It ranks among the world’s top public restaurant brands with a global enterprise of more than 17,000 stores in over 90 markets. Domino’s had global retail sales of over $14.3 billion in 2019, with over $7.0 billion in the U.S. and nearly $7.3 billion internationally. In the fourth quarter of 2019, Domino’s had global retail sales of over $4.5 billion, with over $2.2 billion in the U.S. and over $2.3 billion internationally. Its system is comprised of independent franchise owners who accounted for 98% of Domino’s stores as of the fourth quarter of 2019. Emphasis on technology innovation helped Domino’s achieve more than half of all global retail sales in 2019 from digital channels, primarily online ordering and mobile applications. In the U.S., Domino’s generates over 65% of sales via digital channels and has developed several innovative ordering platforms, including those developed for Google Home, Facebook Messenger, Apple Watch, Amazon Echo and Twitter – as well as Domino’s Hotspots^®, an ordering platform featuring over 200,000 unique, non-traditional delivery locations. In June 2019, through an announced partnership with Nuro, Domino’s furthered its exploration and testing of autonomous pizza delivery. In late 2019, Domino’s opened the Domino’s Innovation Garage adjacent to its headquarters in Ann Arbor, Michigan, to fuel continued technology and operational innovation – while also launching its GPS technology, allowing customers to follow the progress of the delivery driver from store to doorstep.

Order – dominos.com
AnyWare Ordering – anyware.dominos.com
Company Info – biz.dominos.com
Twitter – twitter.com/dominos
Facebook – facebook.com/dominos
Instagram – instagram.com/dominos
YouTube – youtube.com/dominos

Please visit our Investor Relations website at biz.dominos.com to view news, announcements, investor presentations, earnings releases and conference webcasts.

Photo – https://mma.prnewswire.com/media/1141634/FEED_THE_NEED_IMAGE.jpg
Logo – https://mma.prnewswire.com/media/330435/dominos_pizza_new_logo.jpg

SOURCE Domino’s Pizza

Solis Health Plans Provides Medical Staff For COVID-19 Testing Site In Hialeah

April 4, 2020

MIAMI, April 4, 2020 /PRNewswire-HISPANIC PR WIRE/ — Solis Health Plans, a Medicare Advantage Plan, is pleased to join the effort to bring COVID-19 testing to South Florida senior citizens. Under the leadership of Former State Senator Rene Garcia and Miami-Dade County Commissioner Esteban Bovo, Solis and PrimeCare Family Medical Centers are providing staff and personal protective equipment to assist with coronavirus testing at Amelia Earhart Park in the City of Hialeah as of Thursday, April 2nd.

The COVID-19 drive-thru testing center will focus on testing residents aged 65 or older who are experiencing symptoms of the coronavirus. Testing will only be offered for those who meet the criteria and have scheduled an appointment in advance by calling 305-COVID-19 (305-268-4319). The call center opens at 9:00 a.m. daily and will remain open until the appointment slots for the following day are filled. Individuals arriving in cars will be accepted. No walk-ins, bikes or mopeds are allowed. Individuals being tested must sit by a working window and only two individuals are permitted in the vehicle: driver and passenger. The test kits have been donated by Testing Matters.

“Solis Health Plans is dedicated to helping the South Florida community get access to coronavirus testing,” said Solis Health Plans CEO Daniel Hernandez. “Our top priority is getting our community the medical attention they need as quickly and easily as possible. We thank former Senator Garcia and Commissioner Bovo for allowing us to participate in this important endeavor.”

Individuals with an appointment should enter Amelia Earhart Park (401 E 65th Street, Hialeah, FL 33013) through the entrance at Palm Avenue and 65th Street in Hialeah. The testing will take place at the rotunda immediately adjacent to the entrance.

About Solis Health Plans
Solis Health Plans is a community-focused Florida Medicare Advantage health plan that delivers outstanding member experience and exceptional service to its members, providers and brokers and offers competitive plans with expanded benefits in multiple counties. The company is locally based and self-identifies as the Un-Corporate Plan: personal as opposed to bureaucratic, innovative instead of risk-averse, and accountable rather than ambiguous. Solis Health Plans is committed to exceeding expectations and to being the plan of choice for the communities served, with the goal of achieving better healthcare outcomes.

For more information on Solis Health Plans, please visit www.solishealthplans.com.

Solis Health Plans is an HMO with a Medicare contract and a contract with the Florida Medicaid Program. Enrollment in Solis Health Plans depends on contract renewal.

Logo – https://mma.prnewswire.com/media/1033320/Solis_Logo_Logo.jpg

SOURCE Solis Health Plans, Inc.

FIBRA Prologis Announces Annual Certificate Holders Meeting

April 3, 2020

MEXICO CITY, April 3, 2020 /PRNewswire-HISPANIC PR WIRE/ — FIBRA Prologis (BMV: FIBRAPL 14), a leading owner and operator of Class-A industrial real estate in Mexico, today announced it will host its annual certificate holders meeting Tuesday, April 21, 2020, at 11:00 a.m. CT.

The meeting is open to FIBRA Prologis certificate holders of record as of April 20, 2020. The meeting agenda includes review and approval of audited 2019 financial statements; approval of the 2019 annual report; ratification of independent members (primary and/or alternate) of the technical committee; confirmation of the members’ independence; and ratification of compensation for such members.

Holders that intend to attend the Holders Meeting shall submit to the offices of the Common Representative at Av. Paseo de la Reforma No. 284 piso 9, Col. Juárez, C.P. 06600, Mexico City, Mexico, to the attention of Jesús Abraham Cantú Orozco, Rebeca Eríves Sepúlveda y/o Martha Corona Benavides, from 11:00 to 15:00 hours, from Monday to Friday, no later than the business day prior to the date of such Holders Meeting: (i) the deposit certificate issued by S.D. Indeval Institución para el Depósito de Valores, S.A. de C.V., (ii) if applicable, the list that for such purposes is issued by the corresponding custodian, and (iii) if applicable, the proxy letter duly signed before two witnesses, or the power of attorney for representation at the Holders Meeting granted under applicable law. When delivering the documentation referred to in this paragraph, the Common Representative will provide the Holders of the Certificates with the necessary information regarding the telephone and/or digital platform which will be used for the Meeting. The Holders are free to contact the Common Representative, either via email ([email protected]) or by telephone (+52 55) 5231-0848 with any questions related to the scope of the agenda.

For more information, please visit the Investor Relations section of the FIBRA Prologis website at www.fibraprologis.com.

ABOUT FIBRA PROLOGIS

FIBRA Prologis is a leading owner and operator of Class-A industrial real estate in Mexico. As of December 31, 2019, FIBRA Prologis was comprised of 191 logistics and manufacturing facilities in six industrial markets in Mexico totaling 34.9 million square feet (3.2 million square meters) of gross leasable area.

FORWARD-LOOKING STATEMENTS

The statements in this release that are not historical facts are forward-looking statements. These forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which FIBRA Prologis operates, management’s beliefs and assumptions made by management. Such statements involve uncertainties that could significantly impact FIBRA Prologis financial results. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements, which generally are not historical in nature. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to rent and occupancy growth, acquisition activity, development activity, disposition activity, general conditions in the geographic areas where we operate, our debt and financial position, are forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. Although we believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, we can give no assurance that our expectations will be attained and therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. Some of the factors that may affect outcomes and results include, but are not limited to: (i) national, international, regional and local economic climates, (ii) changes in financial markets, interest rates and foreign currency exchange rates, (iii) increased or unanticipated competition for our properties, (iv) risks associated with acquisitions, dispositions and development of properties, (v) maintenance of real estate investment trust (“FIBRA”) status and tax structuring, (vi) availability of financing and capital, the levels of debt that we maintain and our credit ratings, (vii) risks related to our investments (viii) environmental uncertainties, including risks of natural disasters, and (ix) those additional factors discussed in reports filed with the “Comisión Nacional Bancaria y de Valores” and the Mexican Stock Exchange by FIBRA Prologis under the heading “Risk Factors.” FIBRA Prologis undertakes no duty to update any forward-looking statements appearing in this release.

Non-Solicitation – Any securities discussed herein or in the accompanying presentations, if any, have not been registered under the Securities Act of 1933 or the securities laws of any state and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and any applicable state securities laws. Any such announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein or in the presentations, if and as applicable.

Logo – https://mma.prnewswire.com/media/528012/FIBRA__Logo.jpg

SOURCE FIBRA Prologis

Trial for Potential Coronavirus Treatment is Underway at Montefiore and Einstein

April 3, 2020

BRONX, N.Y., April 3, 2020 /PRNewswire-HISPANIC PR WIRE/ — Montefiore Health System and Albert Einstein College of Medicine has joined a clinical trial to evaluate the experimental drug remdesivir to treat people who are hospitalized with severe COVID-19 infection. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial. This treatment has the potential to help people who have serious lung complications as a result of COVID-19. Recruitment for the trial began in March and is still underway.

Montefiore-Einstein is one of 46 testing sites nationwide and is the first site in New York State to open. NIAID launched the multi-center international effort to determine if remdesivir, a broad-spectrum antiviral drug, acts against COVID-19 viral infection. Remdesivir has shown promise in animal models of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), both caused by human coronaviruses.

The randomized, double-blind, placebo-controlled trial is being led by principal investigator Barry Zingman, M.D., professor of medicine at Einstein and clinical director, infectious diseases, in the Moses division of Montefiore Health System. The trial is “adaptive,” meaning it can be modified to include other investigational treatments. “This flexibility allows us to add additional therapies to the trial step-by-step to improve treatment as the pandemic continues,” said Dr. Zingman.

Trial participants are hospitalized patients with a laboratory-confirmed coronavirus infection and lung complications, including rattling sounds when breathing, a need for supplemental oxygen, abnormal chest X-rays showing pneumonia, or the need for a mechanical ventilator.

People in the treatment group will receive 200 mg of remdesivir intravenously on the first day of their enrollment in the study and will receive another 100 mg each day for the duration of hospitalization, for up to 10 days total. The placebo group will receive an equal volume of a solution that resembles remdesivir but contains inactive ingredients.

Montefiore and Einstein’s robust clinical trial infrastructure contributed to its selection and rapid approval for participation.

No therapies have yet been approved by the U.S. Food and Drug Administration for treating COVID-19.

Remdesivir, an investigational antiviral therapy, was developed by Gilead Sciences, Inc.

About Montefiore Health System
Montefiore Health System is one of New York’s premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 11 hospitals, including the Children’s Hospital at Montefiore, Burke Rehabilitation Hospital and more than 200 outpatient ambulatory care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube.

About Albert Einstein College of Medicine
Albert Einstein College of Medicine is one of the nation’s premier centers for research, medical education and clinical investigation. During the 2019-20 academic year, Einstein is home to 724 M.D. students, 158 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 265 postdoctoral research fellows. The College of Medicine has more than 1,800 full-time faculty members located on the main campus and at its clinical affiliates. In 2019, Einstein received more than $178 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and an affiliation network involving hospitals and medical centers in the Bronx, Brooklyn and on Long Island. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.

Logo – https://mma.prnewswire.com/media/675671/Montefiore_Logo.jpg

SOURCE Montefiore Health System; Albert Einstein College of Medicine

Purchasers of Charmin Freshmates Flushable Wipes: A Class Action Settlement May Affect Your Rights

April 3, 2020

PHILADELPHIA, April 3, 2020 /PRNewswire-HISPANIC PR WIRE/ — The following statement is being issued by HF Media LLC regarding the Charmin Freshmates Class Action Settlement.

WHO IS AFFECTED?

A class action settlement has been reached involving Charmin Freshmates Flushable Wipes. The settlement involves all pre-moistened wipes sold under the Charmin brand name bearing the word “flushable” on the package label (“Wipes”). The lawsuit claims that the Wipes are not actually flushable. P&G denies these allegations and maintains that the Wipes perform as advertised. You may be an eligible class member if you purchased the Wipes in the State of New York, between May 23, 2011 and March 6, 2020.

WHAT DOES THE SETTLEMENT PROVIDE?

In connection with this settlement, The Procter & Gamble Company (“P&G”) will change the labeling of the Wipes and agreed to stricter industry-standard testing protocols. P&G will also pay a partial cash refund of (i) seventy cents ($0.70) per package purchased, up to $6.30 per Household without proof of purchase; or (ii) one dollar and twenty cents ($1.20) for the first package with proof of purchase (and $1.00 for any additional packages with proof of purchase), up to $50.20 per Household with proof of purchase. Proof of purchase means the actual label or bar code portion of the package of the Product (not a photocopy or digital image), or the original or photocopy or digital image of an itemized sales receipt originally generated by a retail seller showing the date and place of purchase, name of the product purchased, and the amount paid.

WHAT ARE MY OPTIONS?

You must submit a claim online by September 21, 2020 or by mail so that it is received (not merely postmarked) no later than September 21, 2020 to receive a payment. The deadline may be extended, please check the website for updates.

You can opt out of the class and keep your right to sue P&G on the released claims by June 25, 2020. The settlement will release all claims related to Plaintiff’s contentions that P&G’s marketing, advertising, and sale of the Wipes with the representations “flushable,” “septic safe,” and “safe for sewer and septic systems” were false or misleading. There is no release of claims for personal injury or property damage allegedly caused by use of the Wipes.

You can also object to the settlement by June 25, 2020, which does not affect your ability to file a claim. For details on how to opt out, object, or to file a claim, please visit www.BelfioreWipeSettlement.com or contact the Claim Administrator.

If you do nothing you will not receive a payment and you will be bound by the decisions of the Court.

COURT HEARING AND ATTORNEYS’ FEES

The Court will hold a hearing on July 23, 2020 at 11:00 a.m. ET to consider whether to approve the settlement. If the settlement is approved, the attorneys for the class will ask the Court for an award from P&G of up to $3,200,000 in fees, costs, and expenses, and a class representative payment of $10,000 for the named plaintiff. Note that the hearing date may change without further notice to you although any such change will be reflected on the website. You may attend the hearing, but you do not have to. Plaintiff’s Motion for Attorneys’ Fees and Costs will be posted on the settlement website after it is filed.

MORE INFORMATION

This is only a Summary. For more information, please visit: www.BelfioreWipeSettlement.com or contact the Claim Administrator by calling 1 (833) 930-2423 or writing to Belfiore v. P&G, PO Box 34880, Philadelphia, PA, 19101-4880. You may also contact Plaintiff’s counsel, Wolf Popper LLP, 845 Third Avenue, New York NY 10022. The case name is Belfiore v. Procter & Gamble Company, U.S District Court for the Eastern District of York Case No. 2:14-cv-04090.

SOURCE HF Media LLC

Through COVID-19 Pandemic, Seaboard Marine Carries Your Critical Commodities

April 3, 2020

PortMiami has three cargo terminals with Seaboard Marine exclusively operating an 87-acre facility. The Seaboard Marine facility at PortMiami has remained fully operational and open, pictured here unloading critical commodities during the COVID-19 situation.

MIAMI, April 3, 2020 /PRNewswire-HISPANIC PR WIRE/ — For nearly 40 years, Seaboard Marine has served the Western Hemisphere carrying cargo to some of the world’s hardest-hit countries in the aftermath of natural disasters. But, no situation has come close to the recent pandemic affecting nearly every country on earth. This extraordinary epidemic has tested the limits of our business continuity protocols. The urgency of this situation has also strengthened our partnerships with federal and local governments as well as our most loyal customers who import and export critical commodities that help fight the spread of the novel coronavirus COVID-19.

Since the spread of the virus, Seaboard Marine has been working with various seaport and government officials, both within the U.S. and abroad, to ensure we can continue to operate as an essential service while making necessary adjustments to ensure the expeditious transport of cargo and supplies. Many of our customers throughout the United States and Latin America contribute tremendously to meeting the need for critical products such as medical supplies, pharmaceuticals, and food.

One of those customers is DeRoyal, a manufacturer of medical supplies, with facilities throughout the U.S., as well as manufacturing plants in Costa Rica, Dominican Republic, and Guatemala. Elizabeth Reed, Sr. Director of Quality and Regulatory at DeRoyal, said, “Seaboard Marine is a critical transportation service supplier of raw materials to DeRoyal for manufacturing of medical products. These medical products are sold directly to hospitals, trauma centers, group purchasing organizations, and physician offices. DeRoyal depends on Seaboard Marine to continuously transport containers with material to enable us to actively sustain our global supply of finished medical products.”

Governments throughout Latin America and the Caribbean, like their counterparts in the U.S. and elsewhere in the world, have recently placed varying limits on mobility and certain types of work. Most, though, have recognized the importance of international trade, particularly essential commodities. Nonetheless, it has been challenging, at times, to meet the transportation needs of our customer’s factories. But all of the offices within the Seaboard network including those overseas are ensuring that cargo containers, trucks, and needed local paperwork are provided, so the urgently manufactured masks and gowns are promptly delivered via Seaboard Marine ships for quick transit.

In addition to threatening lives, this pandemic has interrupted the normal order of society. However, not all dissimilar to a natural disaster, business continuity is in our blood, and we are always prepared in advance. With over 90% of our office-based staff now working remotely while also keeping our cargo terminals and vessels operating at a high standard, we work with our customers to use our combined assets and infrastructure to urgently fight against the spread of the virus, case in point SanMar.

Seattle-based SanMar is an award-winning supplier of apparel and accessories to 22 retail, private label, and mill brands. John Janson, Global Logistics Director at SanMar, said, “As the nation’s largest supplier of wholesale apparel, SanMar has been moved by the impact of this pandemic. We’re now working in a consortium, with other large apparel manufacturers, to quickly produce five hundred million medical masks for the U.S. healthcare industry. Leveraging our factories in Haiti and Honduras, we rely on Seaboard Marine’s dedicated service to PortMiami to transport these critical medical items throughout the United States.”

Juan Kuryla, Director at PortMiami, said, “Seaboard Marine, a long-time incredible partner, is noted for their efficiency and schedule integrity. We know that vessels carrying these critical medical supplies made in nearby factories in Central America, Haiti, and the Dominican Republic must promptly discharge for these cargoes to quickly reach doctors and hospitals in the U.S. The entire PortMiami family including the U.S. Coast Guard, Customs and Border Protection, longshoremen and our security team are proudly committed to helping make it happen.”

Media Contact:
Chris Concepcion
[email protected]

Photo – https://mma.prnewswire.com/media/1141119/Seaboard_Marine_Vessels_at_Berth_at_PortMiami.jpg

SOURCE Seaboard Marine Ltd. Inc.

March of Dimes Encourages People to Step Up! to Support Moms and Babies during the COVID-19 Pandemic

April 2, 2020

ARLINGTON, Virginia, April 2, 2020 /PRNewswire-HISPANIC PR WIRE/ — March of Dimes today launched a new virtual campaign, called Step Up!, to raise vital support for moms and babies during the COVID-19 pandemic causing the ongoing global health crisis. The new virtual fundraiser will replace this year’s March of Dimes’ annual in-person March for Babies events that for the past 50 years have seen thousands of people march as a way to fundraise. Due to social distancing and stay-in-place orders, March of Dimes is encouraging supporters across the country to Step Up! by taking part in a virtual walk – safely at home or wherever they can – in order to support moms and babies during their greatest time of need.

“It is imperative that moms and babies have access to the care and resources required for a healthy start each and every day, and the need has become even more critical in our current environment,” said Stacey D. Stewart, President and Chief Executive Officer of March of Dimes. “During this unprecedented time, March for Babies Step Up! is so vitally important because through the incredible fundraising efforts of our supporters, we can continue to help moms and babies as well as learn more about this novel disease. We are so thankful our supporters are able to virtually participate in this innovative fundraising activity that will make a difference in the lives of families everywhere.”

Beginning today, March for Babies is asking participants to register to virtually march at marchforbabies.org. The virtual March for Babies will commence across the country with participants tracking their steps using smart phones or fitness watches and collecting donations for their steps. Every step will be tracked and totaled through the Charity Miles mobile app, culminating in a virtual celebration on May 15. Participants will also have the opportunity to engage in a series of fun, virtual challenges throughout the campaign to boost their step count, share personal stories about why they’re “stepping up” and ultimately raise awareness of the critical needs of mothers and babies right now.

“Expecting mothers can’t pause pregnancy. The COVID-19 pandemic is putting a strain on the healthcare system, and at this time, the health risks to moms and babies remain mostly unknown, however they are the ones who depend on the health system for support from pregnancy through delivery,” shared Dr. Rahul Gupta, Senior Vice President and Chief Medical and Health Officer at March of Dimes. “There is an urgent need, due to the COVID-19 pandemic, to support families with a baby in the Neonatal Intensive Care Unit (NICU) and ensure that moms-to-be have the latest health information to protect themselves and their infants.”

Even in the best of times, moms and babies rely on March of Dimes programs, research, advocacy and health information. There are families right now imagining preparing to labor or new parents concerned for their baby in the NICU, and that is why March for Babies will proceed, but in a new way.

“I believe the March of Dimes mission to support and protect moms and babies has never been more urgent than it is today and I’m honored to have been able to help kick off the Step Up! campaign through a virtual launch event last week,” shared Eli Manning, retired New York Giants Quarterback and New York City March for Babies Vice Chairman. “March of Dimes is an organization built on the idea that when we come together, we can achieve great things. And, honestly this year’s March for Babies seemed unlikely, but we worked to develop a game plan, and the simple answer is – we will all ‘step up’ to help raise critical funds needed during this unprecedented time.”

For more than 80 years, March of Dimes has pioneered research, led programs, provided educational resources and enabled policy change so that every mom and baby can have the best possible start. The funds raised through Step Up! will continue to support research for COVID-19 treatments that are safe for pregnant and lactating moms, fundraising and advocacy efforts needed to help those families directly impacted by COVID-19, resources and training for doctors and nurses in the ICU and NICU, and the development of educational materials for moms-to-be and families about what they should know to protect themselves.

For more information on how to sign up to Step Up! and fundraise, please visit www.marchforbabies.org. To download the Charity Miles app, click here from your mobile device to download the Charity Miles App. Step along with us on Facebook, Instagram and Twitter, and share your journey using #MarchforBabies and #MFBStepUp!

About March of Dimes
March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every baby can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we empower every mom and every family. Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook and follow us on Instagram and Twitter.

Logo – https://mma.prnewswire.com/media/513643/March_of_Dimes_Foundation_Logo.jpg

Logo – https://mma.prnewswire.com/media/1140945/MFBStepUp_Logo.jpg

SOURCE March of Dimes

(Español) La FDA solicita el retiro del mercado de todos los productos hechos a base de ranitidina (Zantac)

April 2, 2020

U.S. Food and Drug Administration (FDA) logo

Sorry, this entry is only available in Español.

Tablo® Hemodialysis System Receives FDA Clearance for Home Dialysis

April 2, 2020

SAN JOSE, Calif., April 2, 2020 /PRNewswire-HISPANIC PR WIRE/ — Outset Medical, a leading med tech innovator delivering first-of-its-kind technology into the growing global dialysis market, today announced the Food and Drug Administration (FDA) cleared the Tablo Hemodialysis System for patient use in the home. The new home clearance expands Tablo’s existing labeled indication for use in acute and chronic care facilities, which for the first time enables healthcare providers the same dialysis machine from the ICU to the home.

Tablo enters the market at a critical time in the midst of the COVID-19 pandemic and renewed national focus on home dialysis for improving patient outcomes while lowering cost. In mid-2019, President Trump and United States Department of Health and Human Services Secretary Alex Azar announced an Executive Order to help Americans with kidney failure. A major component of the policy was ensuring 80% of all new dialysis patients start therapy at home or get transplanted by 2025. The emergence of COVID-19 further heightens the urgency for giving current in-center dialysis patients the option to treat at home.

“Tablo was designed to simplify dialysis, making it easier and more accessible for patients to take advantage of the safety, convenience and flexibility of dialyzing at home,” said Outset Medical Chief Executive Officer, Leslie Trigg. “We are proud to offer them this new, life-enhancing option, particularly in light of the COVID-19 related challenges dialysis patients and providers are experiencing.”

Currently, more than 500,000 Americans undergo dialysis treatments three or more times each week, typically lasting four hours per treatment. Approximately 100,000 new patients start treatment annually. Yet only 12% receive it at home where they’re more comfortable, productive and empowered.

POSITIVE TRIAL RESULTS

A prospective, multicenter, home hemodialysis trial with 30 patients was completed in 2019 and confirmed the Tablo system is safe and effective for home use. The results were published in November 2019 in Hemodialysis International.

Troy Plumb, M.D., the principal study investigator and the Division Chief of Nephrology and Associate Professor of Medicine at the University of Nebraska Medical Center College of Medicine in Omaha, said, “My patients, colleagues and I are excited for Tablo to be available for home use. The trial made it clear the system is easy to learn and performs well in the home environment. I believe that Tablo will open up opportunities for patients to pursue home hemodialysis and take more control over their lives and care.”

One of those patients is 62-year-old Texas resident and technology consultant Richard Crawford. He has had a kidney transplant that lasted 17 years and is currently on a transplant list. Over the years, he has had thousands of dialysis treatments at various centers as well as on home hemodialysis. He found using Tablo at home to be very intuitive, allowing him to dialyze while remaining productive during treatment.

“The home part of the Tablo trial only lasted eight weeks, but was eye opening,” he said. “The system is extremely easy to set up and use, so I wasn’t wasting hours on dialysis-related tasks. I was able to work at my desk during treatments, which was wonderful for my productivity. The system provided me with a new level of independence due to the ease of setup and maintenance. “When the trial ended and they had to pick up the Tablo, I tried talking them out of it. I really hated seeing it go.”

Outset will begin a controlled rollout for home use at select sites over the coming months to ensure the highest level of training and support for Tablo home patients. This program will be balanced with the need to supply health systems, hospitals, and clinics with devices to support a surge of demand for dialysis treatments driven by COVID-19. More information about availability for patients and providers can be found at www.outsetmedical.com.

Tablo was designed in Silicon Valley to reduce the cost and complexity of dialysis care. Requiring only an electrical outlet and tap water to operate, the mobile Tablo system frees patients and providers from expensive clinic infrastructure. The machine’s functionality enables it to serve as a dialysis clinic on wheels. Wireless data, sensor-based automation and an animated touchscreen make the system easy to learn and use. Leading health systems and medical centers across the U.S. use Tablo for hospital and clinic dialysis, and the U.S. Department of Health and Human Services (HHS) awarded a contract for the use of Tablo in communities hit by natural disasters.

Award Winning Technology

Last April, Outset was a winner of the KidneyX Redesign Dialysis Competition, a partnership between the U.S. Department of Health and Human Services and the American Society of Nephrology to support innovative strategies for tackling kidney disease. Outset’s winning concept marries data from Tablo’s unique sensors and automation systems with physiologic data from the patient with an eye toward creating personalized dialysis treatments that improve patient outcomes.

Outset’s Tablo System was also recently recognized with a Gold Edison Award in the medical patient experience category. The Edison Awards honor game-changing innovations at the forefront of new product and service development, marketing and human-centered design. Nominees were judged by a panel of more than 3,000 leading business executives including past award winners, academics and leaders in the fields of product development, design, engineering, science and medicine. Tablo received the top prize in its category, the Gold Award.

ABOUT OUTSET MEDICAL

Silicon Valley-based Outset Medical is dedicated to technology-driven service model innovation aimed at reducing cost and transforming the patient care experience. Outset’s Tablo System is FDA-cleared for use in acute, chronic care and home settings. For more information visit www.outsetmedical.com and follow the company on Twitter at @OutsetMedical.

GENERAL CONTACT

www.outsetmedical.com

SOURCE Outset Medical, Inc.

COVID Care’s COVID-19 IgG and IgM Rapid Test has been authorized pursuant to FDA EUA guidance, for immediate distribution to Medical Professionals

April 2, 2020

LOS ANGELES, April 1, 2020 /PRNewswire-HISPANIC PR WIRE/ — Molecule Holdings is thrilled to announce it is now providing FDA Approved Rapid COVID-19 Test Kits to Medical Professionals, First Responders, and Law Enforcement. This test detects IgG and IgM antibodies to SARS-CoV-2 in human blood. The Covid Care Rapid Test has a 91% Clinical Sensitivity rating, and a 99% Clinical Specifity rating.

RESULTS IN AS FAST AS 5 MINUTES

Medical professionals are adamant just how critical it is to have access to rapid, point of care testing, that is both simple and affordable. PCR testing technology takes multiple days to yield results and is not a scalable or an affordable solution to answering the extent of community and worldwide COVID-19 testing needs.

The COVID Care testing kits are FDA Approved under the Emergency Use Act and come from Pinnacle BioLabs, an FDA registered laboratory in Tennessee. They are manufactured in an ISO-13485 Certified Facility. The kits have undergone significant preliminary clinical testing and the results are in…

COVID Care tests return results with Diagnostic Specificity higher than 90%!

Testing with the COVID Care test is easy and resembles the tests diabetics use to test their blood sugar.

Simply “prick” a finger with the included lance, drip 2 drops of blood into the included testing cassette, drip 2 drops of testing solution into the cassette, and wait approximately 5 minutes for results. Interpreting results is a very straightforward process.

Photo – https://mma.prnewswire.com/media/1139466/COVID_19_Testing_Kit.jpg

SOURCE Molecule Holdings

1...2,0282,0292,030...3,055 Page 2,029 of 3,055